AMH Equity Ltd Raises Position in SCYNEXIS, Inc. (NASDAQ:SCYX)

AMH Equity Ltd raised its position in shares of SCYNEXIS, Inc. (NASDAQ:SCYX) by 4.3% during the 4th quarter, HoldingsChannel.com reports. The fund owned 626,052 shares of the company’s stock after acquiring an additional 26,052 shares during the period. AMH Equity Ltd’s holdings in SCYNEXIS were worth $758,000 as of its most recent SEC filing.

Separately, Geode Capital Management LLC lifted its stake in shares of SCYNEXIS by 10.0% in the 3rd quarter. Geode Capital Management LLC now owns 398,856 shares of the company’s stock valued at $594,000 after purchasing an additional 36,405 shares during the period. 54.37% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, StockNews.com raised SCYNEXIS from a “sell” rating to a “hold” rating in a research note on Friday, November 8th.

SCYNEXIS Price Performance

NASDAQ:SCYX opened at $1.02 on Thursday. SCYNEXIS, Inc. has a 1-year low of $0.90 and a 1-year high of $3.07. The company has a market capitalization of $38.71 million, a PE ratio of -1.38 and a beta of 1.52. The firm’s 50-day moving average price is $1.12 and its 200-day moving average price is $1.31.

SCYNEXIS Company Profile

SCYNEXIS, Inc, a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC.